OncoMatch/Clinical Trials/NCT04728724
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
Is NCT04728724 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Sintilimab and Chemotherapy for non-small cell lung cancer stage iii.
Treatment: Sintilimab · Chemotherapy — This is a phase II, non-randomized, open-label, multi-center study to evaluate the efficacy of neoadjuvant Sintilimab (PD-1 antibody) or combined with chemotherapy as first-line treatment in patients with stage III non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR activating mutation
Non-squamous cell carcinoma with EGFR active mutation positive
Excluded: ALK rearrangement
Non-squamous cell carcinoma with ... ALK rearrangement
Disease stage
Required: Stage III
stage III confirmed by imageological examinations (CT, PET-CT or EBUS); Without systematic metastasis (including M1a, M1b and M1c)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic anti-cancer treatment for thymic epithelial tumor
Participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment
Cannot have received: Chinese medicine against cancer
Administration of any Chinese medicine against cancer before administration of the drug
Lab requirements
Blood counts
ANC count ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥90 g/L; INR and PT < 1.5×ULN; APTT ≤1.5×ULN
Kidney function
Liver function
Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN, or ≤5×ULN in patients with liver metastatic tumor
Patients with good function of other main organs (liver, kidney, blood system, etc.): ... see details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04728724 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR activating mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK rearrangement is an exclusion criterion.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages